港股异动 | 荃信生物-B(02509)涨超5% 乌司奴单抗注射液新适应症补充申请获NMPA受理

智通财经12-03

智通财经APP获悉，荃信生物-B(02509)涨超5%，截至发稿，涨5.57%，报11.38港元，成交额73.66万港元。消息面上，12月2日，华东医药全资子公司杭州中美华东制药有限公司（简称“中美华东”）收到国家药品监督管理局（NMPA）签发的《受理通知书》（受理号：CYSB2400311），由中美华东申报的乌司奴单抗注射液（研发代码：HDM3001/QX001S）用于儿童斑块状银屑病的补充申请...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488959687?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-03 13:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488959687","market":"us","top_or_hot":-1,"title":"港股异动 | 荃信生物-B(02509)涨超5% 乌司奴单抗注射液新适应症补充申请获NMPA受理","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，荃信生物-B(02509)涨超5%，截至发稿，涨5.57%，报11.38港元，成交额73.66万港元。消息面上，12月2日，华东医药全资子公司杭州中美华东制药有限公司（简称“中美华东”）收到国家药品监督管理局（NMPA）签发的《受理通知书》（受理号：CYSB2400311），由中美华东申报的乌司奴单抗注射液（研发代码：HDM3001/QX001S）用于儿童斑块状银屑病的补充申请...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1219528.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 荃信生物-B(02509)涨超5% 乌司奴单抗注射液新适应症补充申请获NMPA受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 荃信生物-B(02509)涨超5% 乌司奴单抗注射液新适应症补充申请获NMPA受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 13:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1219528.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，荃信生物-B(02509)涨超5%，截至发稿，涨5.57%，报11.38港元，成交额73.66万港元。消息面上，12月2日，华东医药全资子公司杭州中美华东制药有限公司（简称“中美华东”）收到国家药品监督管理局（NMPA）签发的《受理通知书》（受理号：CYSB2400311），由中美华东申报的乌司奴单抗注射液（研发代码：HDM3001/QX001S）用于儿童斑块状银屑病的补充申请...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1219528.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1219528.html","article_id":"2488959687","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488959687","pubTimestamp":1733205161,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，荃信生物-B涨超5%，截至发稿，涨5.57%，报11.38港元，成交额73.66万港元。消息面上，12月2日，华东医药全资子公司杭州中美华东制药有限公司收到国家药品监督管理局签发的《受理通知书》，由中美华东申报的乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获得受理。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"Hong Kong stocks changed, Quanxin Biotech-B (02509) rose more than 5%, and the supplementary application for new indications of ustekinumab injection was accepted by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"智通财经APP获悉，荃信生物-B(02509)涨超5%，截至发稿，涨5.57%，报11.38港元，成交额73.66万港元。消息面上，12月2日，华东医药全资子公司杭州中美华东制药有限公司（简称“中美华东”）收到国家药品监督管理局（NMPA）签发的《受理通知书》（受理号：CYSB2400311），由中美华东申报的乌司奴单抗注射液（研发代码：HDM3001/QX001S）用于儿童斑块状银屑病的补充申请获得受理。QX001S最初由荃信生物自主研发，2020年8月，公司与中美华东达成合作，由双方共同推进QX001S的III期临床试验，中美华东作为上市许可持有人负责中国大陆区域商业化，赛孚士负责产品生产及供应。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488959687"}